This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Aceragen Salute del bilancio
Salute finanziaria criteri di controllo 2/6
Aceragen has a total shareholder equity of $57.3M and total debt of $733.0K, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are $78.5M and $21.1M respectively.
Informazioni chiave
1.3%
Rapporto debito/patrimonio netto
US$733.00k
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | US$2.12m |
| Patrimonio netto | US$57.35m |
| Totale passività | US$21.14m |
| Totale attività | US$78.49m |
Aggiornamenti recenti sulla salute finanziaria
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29Analisi della posizione finanziaria
Passività a breve termine: ACGN's short term assets ($5.6M) do not cover its short term liabilities ($17.9M).
Passività a lungo termine: ACGN's short term assets ($5.6M) exceed its long term liabilities ($3.3M).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: ACGN has more cash than its total debt.
Riduzione del debito: ACGN's debt to equity ratio has increased from 0.1% to 1.3% over the past 5 years.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: ACGN has less than a year of cash runway based on its current free cash flow.
Previsione Cash Runway: ACGN has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.3% each year.